Third-Party Covid-19-Specific Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients with Covid-19
An Open-label single center two arm study to assess the safety and efficacy of COVID-19-specific T cells when given as treatment to adult patients (age ≥ 18 years) with a newly diagnosed COVID-19 infection. This immunologic treatment is aimed at patients, who are at high risk of progression due to their advanced age, or other underlying health conditions.
Actual Study Completion Date: January 19, 2023
For additional information about the study,
call 267-239-6281 or e-mail firstname.lastname@example.org
COVID-19 and Tevogen’s Investigational Therapy
New Jersey, USA
© 2023 Tevogen Bio. All Rights Reserved.